Published in Curr Atheroscler Rep on July 01, 2010
Metabolomics as a tool for cardiac research. Nat Rev Cardiol (2011) 1.51
Reverse-engineering human regulatory networks. Wiley Interdiscip Rev Syst Biol Med (2012) 0.98
Application of comprehensive two-dimensional gas chromatography with time-of-flight mass spectrometry method to identify potential biomarkers of perinatal asphyxia in a non-human primate model. J Chromatogr A (2011) 0.97
Metabolomic profiling for identification of novel potential biomarkers in cardiovascular diseases. J Biomed Biotechnol (2011) 0.93
The heritability of metabolic profiles in newborn twins. Heredity (Edinb) (2012) 0.85
Functional genomics applied to cardiovascular medicine. Circulation (2011) 0.85
The emergence of proton nuclear magnetic resonance metabolomics in the cardiovascular arena as viewed from a clinical perspective. Atherosclerosis (2014) 0.83
Plasma Metabolic Profile Determination in Young ST-segment Elevation Myocardial Infarction Patients with Ischemia and Reperfusion: Ultra-performance Liquid Chromatography and Mass Spectrometry for Pathway Analysis. Chin Med J (Engl) (2016) 0.82
Intervention Trials with the Mediterranean Diet in Cardiovascular Prevention: Understanding Potential Mechanisms through Metabolomic Profiling. J Nutr (2016) 0.78
1H-NMR-based metabolomic analysis of cerebrospinal fluid from adult bilateral moyamoya disease: comparison with unilateral moyamoya disease and atherosclerotic stenosis. Medicine (Baltimore) (2015) 0.76
Systems mapping of metabolic genes through control theory. Adv Drug Deliv Rev (2013) 0.75
Technology platform development for targeted plasma metabolites in human heart failure. Clin Proteomics (2013) 0.75
Large-scale Metabolomic Analysis Reveals Potential Biomarkers for Early Stage Coronary Atherosclerosis. Sci Rep (2017) 0.75
Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med (2005) 28.21
Global mortality, disability, and the contribution of risk factors: Global Burden of Disease Study. Lancet (1997) 25.40
Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med (1990) 17.52
Mechanisms of disease:Molecular and metabolic mechanisms of insulin resistance and beta-cell failure in type 2 diabetes. Nat Rev Mol Cell Biol (2008) 6.23
Molecular networks as sensors and drivers of common human diseases. Nature (2009) 6.14
Shotgun lipidomics: electrospray ionization mass spectrometric analysis and quantitation of cellular lipidomes directly from crude extracts of biological samples. Mass Spectrom Rev (2005) 5.98
Systems biology: Metabonomics. Nature (2008) 5.32
Mass spectrometry-based metabolomics. Mass Spectrom Rev (2006) 5.23
Opinion: understanding 'global' systems biology: metabonomics and the continuum of metabolism. Nat Rev Drug Discov (2003) 4.46
The genetics of plant metabolism. Nat Genet (2006) 4.28
Potential of metabolomics as a functional genomics tool. Trends Plant Sci (2004) 4.10
Rapid and noninvasive diagnosis of the presence and severity of coronary heart disease using 1H-NMR-based metabonomics. Nat Med (2002) 3.91
Integrating genotypic and expression data in a segregating mouse population to identify 5-lipoxygenase as a susceptibility gene for obesity and bone traits. Nat Genet (2005) 3.74
Data processing for mass spectrometry-based metabolomics. J Chromatogr A (2007) 3.21
Metabolomic identification of novel biomarkers of myocardial ischemia. Circulation (2005) 3.16
Validation of candidate causal genes for obesity that affect shared metabolic pathways and networks. Nat Genet (2009) 2.97
Measuring the metabolome: current analytical technologies. Analyst (2005) 2.74
Establishing reporting standards for metabolomic and metabonomic studies: a call for participation. OMICS (2006) 2.72
Metabolomics applied to diabetes research: moving from information to knowledge. Diabetes (2009) 2.68
The metabolomics standards initiative. Nat Biotechnol (2007) 2.54
Metabolite profiling of blood from individuals undergoing planned myocardial infarction reveals early markers of myocardial injury. J Clin Invest (2008) 2.46
Association of the Trp719Arg polymorphism in kinesin-like protein 6 with myocardial infarction and coronary heart disease in 2 prospective trials: the CARE and WOSCOPS trials. J Am Coll Cardiol (2008) 2.21
High heritability of metabolomic profiles in families burdened with premature cardiovascular disease. Mol Syst Biol (2009) 2.21
Toward fingerprinting cellular lipidomes directly from biological samples by two-dimensional electrospray ionization mass spectrometry. Anal Biochem (2004) 2.17
13C NMR isotopomer analysis reveals a connection between pyruvate cycling and glucose-stimulated insulin secretion (GSIS). Proc Natl Acad Sci U S A (2002) 2.04
Metabolomic profiling reveals distinct patterns of myocardial substrate use in humans with coronary artery disease or left ventricular dysfunction during surgical ischemia/reperfusion. Circulation (2009) 2.01
Analytical strategies in metabonomics. J Proteome Res (2007) 2.00
Comparing and combining NMR spectroscopy and mass spectrometry in metabolomics. Anal Bioanal Chem (2007) 1.99
A kinesin family member 6 variant is associated with coronary heart disease in the Women's Health Study. J Am Coll Cardiol (2008) 1.92
Atherosclerosis and liver inflammation induced by increased dietary cholesterol intake: a combined transcriptomics and metabolomics analysis. Genome Biol (2007) 1.80
Family history as an independent risk factor for coronary artery disease. J Am Coll Cardiol (1984) 1.65
Effect of glycaemic control and age on low-density lipoprotein susceptibility to oxidation in diabetes mellitus type 1. Eur Heart J (2001) 1.62
Lipidomics and lipid profiling in metabolomics. Curr Opin Lipidol (2007) 1.58
Proton NMR analysis of plasma is a weak predictor of coronary artery disease. Nat Med (2006) 1.49
Mass spectrometry tools and metabolite-specific databases for molecular identification in metabolomics. Analyst (2009) 1.37
Innate immune signals in atherosclerosis. Clin Immunol (2009) 1.32
Cardiovascular networks: systems-based approaches to cardiovascular disease. Circulation (2010) 1.30
Analysis and comparison of metabolic pathway databases. Brief Bioinform (2001) 1.26
Proteomic and metabolomic analyses of atherosclerotic vessels from apolipoprotein E-deficient mice reveal alterations in inflammation, oxidative stress, and energy metabolism. Arterioscler Thromb Vasc Biol (2005) 1.23
Metabonomic study of biochemical changes in the serum of type 2 diabetes mellitus patients after the treatment of metformin hydrochloride. J Pharm Biomed Anal (2009) 1.07
CE-MS in metabolomics. Electrophoresis (2009) 1.06
First autopsy study of an Okinawan centenarian: absence of many age-related diseases. J Gerontol A Biol Sci Med Sci (2004) 0.98
Mining biological networks for unknown pathways. Bioinformatics (2007) 0.97
Advances in systems biology are enhancing our understanding of disease and moving us closer to novel disease treatments. Genetica (2009) 0.95
Nuclear magnetic resonance-based metabolomics predicts exercise-induced ischemia in patients with suspected coronary artery disease. Magn Reson Med (2008) 0.95
Dietary carbohydrate modification alters serum metabolic profiles in individuals with the metabolic syndrome. Nutr Metab Cardiovasc Dis (2009) 0.92
Metabolomic analysis using optimized NMR and statistical methods. Anal Biochem (2006) 0.90
Plasma fingerprinting with GC-MS in acute coronary syndrome. Anal Bioanal Chem (2009) 0.88
Proteomics and cardiovascular disease: an update. Curr Med Chem (2008) 0.81
Electrophoresis and liquid chromatography/tandem mass spectrometry in disease biomarker discovery. J Chromatogr B Analyt Technol Biomed Life Sci (2008) 0.79
Separation, detection and quantitation of peptides by liquid chromatography and capillary electrochromatography. J Chromatogr A (2008) 0.78
Use of consomic rats for genomic insights into ventilator-associated lung injury. Am J Physiol Lung Cell Mol Physiol (2007) 1.86
Genomic assessment of a multikinase inhibitor, sorafenib, in a rodent model of pulmonary hypertension. Physiol Genomics (2008) 1.14
Feasibility of implementing a comprehensive warfarin pharmacogenetics service. Pharmacotherapy (2013) 1.09
Impact of cardiovascular magnetic resonance on management and clinical decision-making in heart failure patients. J Cardiovasc Magn Reson (2013) 0.98
Effects of trehalose click polymer length on pDNA complex stability and delivery efficacy. Biomaterials (2007) 0.94
Hypoxic response contributes to altered gene expression and precapillary pulmonary hypertension in patients with sickle cell disease. Circulation (2014) 0.92
Association of aldosterone synthase polymorphism (CYP11B2 -344T>C) and genetic ancestry with atrial fibrillation and serum aldosterone in African Americans with heart failure. PLoS One (2013) 0.77
Survival in pulmonary arterial hypertension: A brief review of registry data. Pulm Circ (2011) 0.76
Are men at risk? The role of testosterone in cardiovascular morbidity. Pulm Circ (2012) 0.75